Results 1 to 10 of about 2,856,528 (208)
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond [PDF]
Vaccines, 2023 We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received ...
Joel N. Maslow +8 more
doaj +3 more sources
The future of cancer immunotherapy: DNA vaccines leading the way. [PDF]
Med Oncol, 2023 Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer.
Pandya A +6 more
europepmc +2 more sources
Genome Medicine, 2021 Background Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized cancer immunotherapies. DNA vaccines can be rapidly and efficiently manufactured and can
Lijin Li +17 more
doaj +2 more sources
DNA Vaccines: Their Formulations, Engineering and Delivery. [PDF]
Vaccines (Basel)The concept of DNA vaccination was introduced in the early 1990s. Since then, advancements in the augmentation of the immunogenicity of DNA vaccines have brought this technology to the market, especially in veterinary medicine, to prevent many diseases ...
Kozak M, Hu J.
europepmc +2 more sources
Recent advances in delivery of veterinary DNA vaccines against avian pathogens
Veterinary Research, 2019 Veterinary vaccines need to have desired characteristics, such as being effective, inexpensive, easy to administer, suitable for mass vaccination and stable under field conditions.
Seyed Davoud Jazayeri, Chit Laa Poh
doaj +2 more sources
The DNA Vaccines for the Gn and Gc Heterologous Polymer of Severe Fever with Thrombocytopenia Syndrome Virus Induce Potent Immunogenicity in Mice [PDF]
VaccinesIntroduction/Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) poses a threat to global public health with a mortality rate of up to 30%. However, there is currently no commercialized SFTSV vaccine.
Qiuju He +8 more
doaj +2 more sources
New insights for the development of efficient DNA vaccines [PDF]
Microbial BiotechnologyDespite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical ...
Simone Berger +3 more
doaj +2 more sources
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Journal of Experimental & Clinical Cancer Research, 2019 The recent developments in immuno-oncology have opened an unprecedented avenue for the emergence of vaccine strategies. Therapeutic DNA cancer vaccines are now considered a very promising strategy to activate the immune system against cancer. In the past,
Alessandra Lopes +2 more
doaj +2 more sources
Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses [PDF]
VirusesSingle-dose, immunogenic DNA (iDNA) vaccines coding for whole live-attenuated viruses are reviewed. This platform, sometimes called immunization DNA, has been used for vaccine development for flavi- and alphaviruses.
Peter Pushko +3 more
doaj +2 more sources